Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02057133 · ClinicalTrials.gov registry record · Phase 1

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

A Phase 1 study of Breast Neoplasms, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 1
Development phase
198
Enrollment target
13
Study locations

NCT02057133 is a Phase 1 study of Breast Neoplasms that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 198 participants, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (65% lower). The trial reports 13 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02057133, a Phase 1 study of Breast Neoplasms, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
198 participants
Enrollment target
13
Study locations

Study Summary

This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.

Conditions Studied

Breast Neoplasms

Interventions

  • DRUG Tamoxifen
  • DRUG Anastrozole
  • DRUG Letrozole
  • DRUG Exemestane
  • DRUG LY2835219

Study Locations (13)

Tennessee

  • Peggy and Charles Stephenson Oklahoma Cancer Center - Nashville
  • Tennessee Oncology PLLC - Nashville
  • Vanderbilt University Medical Center - Nashville

New York

  • Columbia University College of Phys & Surgeons - New York
  • Memorial Sloan Kettering Cancer Center - New York

Arkansas

  • Highlands Oncology Group - Duplicate 2 - Rogers

California

  • University of California - San Diego - La Jolla

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic - Rochester

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Oregon

  • Providence Cancer Center Oncology Hematology Care - Portland

Trial Details

FieldValue
Enrollment Target 198 participants
Start Date 2014-03-10
Est. Completion 2026-12
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02057133

The ClinicalTrials.gov registry entry for NCT02057133 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (65% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Tamoxifen is the first listed.

NCT02057133 reports 13 study locations spanning 10 distinct geographic areas - top geographies include Tennessee, New York, Arkansas.

Frequently Asked Questions

What is clinical trial NCT02057133 about?

NCT02057133 is a clinical study titled "A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread". This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to...

What is the current status of trial NCT02057133?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 198 participants. The study started on 2014-03-10. Estimated completion is 2026-12.

What conditions does trial NCT02057133 study?

This clinical trial studies the following conditions: Breast Neoplasms.

What interventions are being tested in trial NCT02057133?

The interventions under investigation include: Tamoxifen (DRUG), Anastrozole (DRUG), Letrozole (DRUG), Exemestane (DRUG), LY2835219 (DRUG).

Who is sponsoring clinical trial NCT02057133?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02057133 being conducted?

This trial has 13 study locations across Arkansas, California, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Neoplasms

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.